Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043823 | 0.79 | POLB (0.39) | POLBGAA | |
| SCHEMBL5671664 | 0.77 | POLB (0.40) | TSHRPOLBGAALMNAALDH1A1 | |
| SCHEMBL6155350 | 0.72 | KDM4E (0.48) | TSHRPOLBGAALMNAFOXM1 | |
| SCHEMBL6154828 | 0.72 | KDM4E (0.48) | TSHRPOLBGAALMNAFOXM1 | |
| SCHEMBL3334310 | 0.71 | TSHR (0.48) | TSHRPOLB | |
| SCHEMBL3334314 | 0.71 | TSHR (0.48) | TSHRPOLB | |
| SCHEMBL4068077 | 0.71 | TSHR (0.44) | TSHRLMNACTSLCTSBCTSK | |
| SCHEMBL5046250 | 0.71 | NPC1 (0.42) | TSHRPOLBGAAALDH1A1 | |
| SCHEMBL6154957 | 0.70 | GAA (0.48) | TSHRPOLBGAALMNAFOXM1 | |
| SCHEMBL5038975 | 0.69 | TSHR (0.45) | TSHRPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677745-A4 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1677745-A2 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050192281-A1 | Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders | RENOVIS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005037208-A2 | NITRONE COMPOUNDS PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192281-A1 | Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders | NLN, NQO1, OPRL1 | TSHR 3020/4885POLB 1120/4885GAA 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.